The Role of Azithromycin in Patients with Cystic Fibrosis

被引：38
|
作者：
Yousef, Abdullah A. [1 ,2 ,3 ]
Jaffe, Adam [2 ,3 ]
机构：
[1] King Faisal Univ, Dept Paediat, Dammam, Saudi Arabia
[2] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia
[3] Sydney Childrens Hosp, Dept Resp Med, Randwick, NSW 2031, Australia
来源：
PAEDIATRIC RESPIRATORY REVIEWS | 2010年 / 11卷 / 02期
关键词：
macrolides; cystic fibrosis; inflammation; azithromycin; BRONCHIAL EPITHELIAL-CELLS; 14-MEMBERED RING MACROLIDES; LONG-TERM AZITHROMYCIN; NECROSIS-FACTOR-ALPHA; PSEUDOMONAS-AERUGINOSA; DIFFUSE PANBRONCHIOLITIS; IN-VITRO; CYTOKINE PRODUCTION; CONTROLLED-TRIAL; ERYTHROMYCIN;
D O I：
10.1016/j.prrv.2009.12.003
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Interest in azithromycin in the management of patients with cystic fibrosis has grown over the last decade. Uniquely this drug has both antibacterial and immune modulating effects which appear to be the reason for its clinical benefit as proven in several well designed clinical studies. In this review we discuss the proposed mechanisms of action of azithromycin and review the evidence for its clinical effectiveness and safety in cystic fibrosis. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：108 / 114
页数：7
相关论文
共 50 条
  • [21] SERUM PHARMACOKINETICS OF EXTENDED RELEASE AZITHROMYCIN IN PEDIATRIC PATIENTS WITH CYSTIC FIBROSIS
    Jacob, S.
    Ramsey, B.
    Shaffer, M.
    Anderson, G.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 323 - 323
  • [22] Mechanisms underlying the increase in mycobacterial infections in cystic fibrosis patients on azithromycin
    Jones, Gareth
    THORAX, 2012, 67 (07) : 599 - 599
  • [23] QTC INTERVAL MONITORING FOR CHRONIC AZITHROMYCIN THERAPY IN PATIENTS WITH CYSTIC FIBROSIS
    Sharpton, R.
    Condren, M.
    O'Neal, K.
    Lloyd, A.
    McIntosh, H.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 353 - 353
  • [24] Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients
    Solleti, Venkata Saran
    Alhariri, Moayad
    Halwani, Majed
    Omri, Abdelwahab
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (03) : 784 - 796
  • [25] Macrolide antibiotics (including azithromycin) for cystic fibrosis
    Southern, Kevin W.
    Solis-Moya, Arturo
    Kurz, Dominiki
    Smith, Sherie
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (02):
  • [26] Azithromycin in non-cystic-fibrosis bronchiectasis
    Fennelly, Kevin P.
    Griffi, David E.
    LANCET, 2013, 381 (9860): : 27 - 27
  • [27] Azithromycin for improving pulmonary function in cystic fibrosis
    Carr, RR
    Nahata, MC
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) : 1520 - 1524
  • [28] Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients
    Wagner, T
    Soong, G
    Sokol, S
    Saiman, L
    Prince, A
    CHEST, 2005, 128 (02) : 912 - 919
  • [29] Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection
    Renna, Maurizio
    Schaffner, Catherine
    Brown, Karen
    Shang, Shaobin
    Tamayo, Marcela Henao
    Hegyi, Krisztina
    Grimsey, Neil J.
    Cusens, David
    Coulter, Sarah
    Cooper, Jason
    Bowden, Anne R.
    Newton, Sandra M.
    Kampmann, Beate
    Helm, Jennifer
    Jones, Andrew
    Haworth, Charles S.
    Basaraba, Randall J.
    DeGroote, Mary Ann
    Ordway, Diane J.
    Rubinsztein, David C.
    Floto, R. Andres
    JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (09): : 3554 - 3563
  • [30] Effects of prolonged use of azithromycin in patients with cystic fibrosis: A meta-analysis
    Florescu, D. F.
    Murphy, P. J.
    Kalil, A. C.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2009, 22 (06) : 467 - 472
12345